On October 30, 2026, Haleon plc received notification that Independent Non-Executive Director Bláthnaid Bergin purchased 7,670 ordinary shares on the London Stock Exchange at a price of £3.242 per share. This transaction was disclosed in accordance with UK Market Abuse Regulation requirements for Persons Discharging Managerial Responsibilities (PDMRs). Haleon plc is a consumer health company focused on everyday health through brands such as Advil, Centrum, and Sensodyne.
